The Scorecard: 3 Month Update: AEHR Sell — Correct so far

This is a Scorecard review, revisiting a past LF0 research call against what actually happened.

Ticker: AEHR Rating: Sell Published: 2026-06-18 Checkpoint: 2026-09-18 Entry price: $115.30 Latest price: $90.55 as of 2026-09-17 Stock return since entry: -21.5% Signal return: +21.5% Verdict: Correct so far

This is the 3-month checkpoint for this call. LF0 publishes monthly Scorecard updates through month 6, using the closest available daily close on or before the checkpoint date.

Read the original LF0 analysis

What I Said

I argued that AEHR’s product differentiation and liquidity were not enough to offset the weak operating backdrop: revenue was still falling sharply year over year, margins were deeply negative, and cash flow was burning. My view was that the valuation left too little room for error unless the company could show sustained improvement in revenue, EBITDA, and cash generation.

Peer Comparison

Why It’s Working (Or Not)

So far, following my Sell call would have earned about 21.5%, because the stock has fallen from my entry price. That outcome is consistent with the original thesis: the weak fundamentals I highlighted have not yet been disproven, and the market has continued to price AEHR more cautiously. The peer group has also been broadly lower over the same stretch, which tells me this has been a tough semiconductor-equipment tape overall, but AEHR’s decline still fits the specific risk I flagged around fragile fundamentals and limited valuation cushion. I do not have evidence here that the revenue, margin, or cash-flow picture has improved enough to invalidate the call.

What Could Still Prove Me Wrong

If AEHR starts showing sustained year-over-year revenue growth, a clear move toward positive EBITDA, and a visible reduction in cash burn, that would directly challenge my thesis. I would also be wrong if the company’s valuation re-rates higher without those operating improvements, because that would mean the market is no longer treating the weak fundamentals as the dominant issue. Until then, the main thing that could still prove me wrong is a real, durable turnaround in the metrics I cited rather than a short-lived bounce.

The June 2026 Cohort

Other directional calls published the same month:

Live LF0 scorecard: The Scorecard | Research Performance dashboard

Past performance does not guarantee future results. Nothing here is investment advice or a recommendation to buy or sell securities. Returns use LF0’s daily-close scorecard methodology.